New collaboration aims to improve patient outcomes and boost biopharma workforce development
A new collaboration between the University of California San Diego Sanford Stem Cell Institute (SSCI) and cell engineering company, MaxCyte, Inc., will improve patient outcomes and boost workforce development in the biopharmaceutical industry.
The joint effort, announced by the two entities in October, will support SSCI’s Advanced Therapy Center (ATC) and the center's Advanced Cell Therapy Laboratory (ACTL) to translate novel engineered therapies into clinical trials, according to Holly Young, M.Sc., ACTL’s facility director.
“Our community and its patients will see a real impact in treatment, both in terms of speed of access and product safety, thanks to this cooperation,” Young said.
What’s more, the collaboration will train the next generation of researchers on the use of MaxCyte’s ExPERT transfection platform, a clinically validated, scalable electroporation system capable of rapidly transfecting anywhere from 75,000 to 20 billion cells.
“We are proud to collaborate with the University of California San Diego SSCI to accelerate the development and scaling of advanced cell therapy programs,” said Maher Masoud, President and CEO of MaxCyte. “By providing our best-in-class electroporation technology and dedicated scientific support, we aim to empower SSCI to advance these transformative therapies from bench to bedside more efficiently. Together, we are committed to expanding access to innovative treatments, ultimately improving the lives of patients in California and beyond.”
Since ATC’s establishment in 2017, the center has served the San Diego-area and Southern California-regional academic and biotechnology industries in transitioning research and development to compliant, clinically relevant manufacturing of cell therapy products for IND-enabling and Phase I/II clinical studies.
To learn more about SSCI and its six centers, including the ATC, visit stemcells.ucsd.edu. To learn more about the ATC, ACTL, and their services, email [email protected].
